SEC Form 4 · accession 0001209191-18-011664
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John McGrath
Officer — EVP & Chief Financial Officer
Period of report
Feb 15, 2018
Accepted (ET)
Feb 20, 2018 · 8:22 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Feb 15, 2018 | S | 6,500 | $46.77 | D | 99,056 | D | |
| Common StockF3 | Feb 15, 2018 | M | 5,132 | $0.00 | A | 104,188 | D | |
| Common Stock | Feb 15, 2018 | F | 2,926 | $47.05 | D | 101,262 | D | |
| Common StockF5 | Feb 16, 2018 | S | 4,000 | $46.93 | D | 97,262 | D | |
| Common StockF6 | Feb 16, 2018 | S | 2,500 | $48.08 | D | 94,762 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF11,F7,F8,F9,F10 | — | Feb 15, 2018 | M | 5,132 | D | — | — | Common Stock | 5,132 | 0 | I |
Explanation of responses
- F1Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016.
- F10The earlier of (i) December 12, 2020 or (ii) the recipient's termination date.
- F11The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee.
- F2The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.50 to $47.25. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3Shares issued upon settlement of vested restricted stock units ("RSUs").
- F4Shares withheld to cover tax obligation from settlement of vested restricted stock units.
- F5The price in Column 4 is a weighted average sale price. The prices actually received ranged from $46.65 to $47.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6The price in Column 4 is a weighted average sale price. The prices actually received ranged from $47.70 to $48.325. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F7Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement.
- F8The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on January 6, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date.
- F9Fully vested.